statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh V. Ph D. Patel sold 25,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average...

Dinesh V. Ph D. Patel Sells 25,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

This indicator may be signaling that PTGX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Protagonist Therapeutics (PTGX, $28.26) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling PTGX's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Protagonist Therapeutics (PTGX, $28.93) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This price move could be a signal that PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Protagonist Therapeutics (PTGX, $28.33) price may climb as it broke lower Bollinger Band on Mar 14, 2024

Protagonist Therapeutics (PTGX, $30.2) entered Downtrend as Momentum indicator drops below 0 level on Mar 13, 2024

This is a Bearish indicator signaling PTGX's price could decline from here. Traders may explore shorting the stock or put options...

Protagonist Therapeutics (PTGX, $30.12) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 11, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Protagonist Therapeutics announces presentation of data on JNJ-2113

This is a signal that PTGX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Protagonist Therapeutics (PTGX, $30.96) RSI Indicator left the overbought zone on March 05, 2024

Protagonist Therapeutics (NASDAQ:PTGX  Free Report) had its price target boosted by JPMorgan Chase  Co. from $34.00 to $37.00 in a research report released on Wednesday, Benzinga reports...

JPMorgan Chase & Co. Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $37.00

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Volume	68,809.00
52-Wk High	$33.34
52-Wk Low	$13.72

Period	Estimated	Reported	Surprise	Result
Q1'24	$1.19	--	--	N/A
Q4'23	$0.04	$0.44	948.87%	BEAT
Q3'23	-$0.66	-$0.58	12.26%	BEAT
Q2'23	-$0.67	-$0.68	-2.07%	MISSED
Q1'23	-$0.73	-$0.67	7.74%	BEAT

PTGX Protagonist Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals